3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
113
Neoplasms
8
HER2-positive Breast Cancer
8
Neoplasm Metastasis
6
Triple Negative Breast Neoplasms
4
Prostatic Neoplasms
4
Pancreatic Neoplasms
4
Inflammatory Breast Neoplasms
4
Hematologic Neoplasms
3
Brain Neoplasms
3
Anatomic Stage I Breast Cancer AJCC v8
3
Salivary Gland Neoplasms
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Locally Advanced Breast Cancer
2
HER2-positive Metastatic Breast Cancer
2
HER2-positive Early Breast Cancer
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Ductal, Breast
2
Breast Neoplasms, Male
2
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Stomach Neoplasms
1
Solid Tumor
1
Skin Neoplasms
1
Sarcoma
1
Interventions
padeliporfin
5
Nivolumab
3
entrectinib
2
cobimetinib
2
capmatinib
2
atezolizumab
2
anlotinib
2
alectinib
2
Vemurafenib
2
Sunitinib
2
Radiosurgery
2
Cyclophosphamide
2
Cisplatin
2
Aspirin
2
Ascorbic Acid
2
trametinib
1
spartalizumab
1
relatlimab
1
pertuzumab
1
pembrolizumab
1
palladium-bacteriopheophorbide
1
olaparib
1
niraparib
1
nintedanib
1
montanide ISA 51
1
lutetium Lu 177 dotatate
1
guadecitabine
1
genexol-PM
1
durvalumab
1
dabrafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasms by Site
×
pertuzumab
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled